H.C. Wainwright raised the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $9 and keeps a Buy rating on the shares post the Q1 report. The firm says the company’s Aucatyzl U.S. demand is growing while the UK launch is off to a positive start.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
- Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M
- Autolus Therapeutics Reports Strong Q1 Growth and Outlook
- Autolus Therapeutics (AUTL) Q1 Earnings Cheat Sheet
- Analyst Maintains Buy on Autolus, Reiterates $9 Price Target on Restructuring Savings and Clinical Catalysts